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During the human immunodeﬁciency virus type 1 (HIV-1) pandemic, continuous, extensive genetic
diversiﬁcation of the virus has been observed. To study the effect of HIV-1 diversiﬁcation on integrase-
associated viral replication capacity (RC), 94 HIV-1 subtype B integrase sequences from two groups of
antiretroviral-naive viruses isolated 15 y apart were ampliﬁed and recombined with an HIV-1 infectious
clone. Viral RC was determined by infecting a T cell line with a long terminal repeat-driven green
ﬂuorescent protein reporter. Signiﬁcant differences in integrase-mediated RC were observed between
recombinant viruses from early and late isolates (p¼0.0286). Integrases from late isolates had
signiﬁcantly lower sequence conservation scores compared to an ancestral subtype B sequence
(po0.0001). Integrase amino acid polymorphisms S17N, I72V, S119P, and D256E were associated with
a lower ex vivo viral RC. These results suggest that integrase sequence diversiﬁcation has affected ex vivo
HIV-1 RC.
& 2013 Elsevier Inc. All rights reserved.Introduction
Since the introduction of the most recent common ancestor of
HIV-1 group M into humans (Sharp and Hahn, 2011), the viral
population has become extraordinarily diverse. Therefore, viral
sequence conservation has decreased over time at the population
level. It has been hypothesized that viral diversiﬁcation has
inﬂuenced HIV-1 virulence over the course of the epidemic
(Arien et al., 2007; Rolland et al., 2007). However, few and
conﬂicting studies have investigated the impact of HIV-1 diversi-
ﬁcation on the ex vivo replication capacity (RC) of HIV-1. Arien
et al. (2005) reported that the mean ex vivo relative RC of
historical (1986–1989) HIV-1 isolates is signiﬁcantly greater than
that of more recent (2002–2003) isolates. This study suggested
that deleterious mutations introduced into the viral population via
the continual introduction of new selective pressures and genetic
bottlenecks may reduce RC or virulence. In contrast, others have
found that recent isolates have higher ex vivo RC than earlier
isolates, suggesting that HIV-1 virulence may be increasing (Gali
et al., 2007). Nevertheless, these studies have not focused on the
impact of HIV-1 diversiﬁcation on HIV-1 RC or, more speciﬁcally,
on the impact of HIV-1 diversiﬁcation on the ﬁtness of individual
viral proteins.ll rights reserved.
tínez).Cytotoxic T lymphocyte (CTL) and antiretroviral drug escape
mutations are detrimental to HIV-1 RC (Leslie et al., 2004;
Martinez-Picado et al., 1999; Nijhuis et al., 1999), yet they may
persist in new hosts in the absence of pressure from drugs or the
immune system. This beneﬁt can diminish over time due to
reversion of the escape mutations (Leslie et al., 2004) or to the
emergence of compensatory substitutions (Martinez-Picado et al.,
1999; Nijhuis et al., 1999). A large cohort study has also shown that
HIV-1 is adapting to human leukocyte antigen (HLA) and CTL host
responses (Kawashima et al., 2009). This study suggested that the
ex vivo RC of HIV-1 may have decreased over time through
mutational escape and loss of active CTL epitopes at the popula-
tion level. Another possible factor affecting the loss of viral ﬁtness
is the genetic bottleneck that occurs during virus transmission.
Indeed, HIV-1 transmission is characterized by an acute genetic
bottleneck in which a single transmitted founder virus frequently
establishes infection (Derdeyn et al., 2004; Keele et al., 2008).
Drastic ex vivo RC losses were observed in HIV-1 upon serial
plaque-to-plaque bottleneck events in MT-4 cells (Yuste et al.,
1999). In this study, analysis of the entire genomic nucleotide
sequences of bottlenecked viruses showed the accumulation of
4–28 mutations per genome.
In a recent study, signiﬁcant reductions in gag-protease-
mediated HIV-1 RC during the course of the epidemic in Japan
were observed (Nomura et al., 2013). In a smaller cohort of 22
patients, we found a reduction in the protease-associated HIV-1 RC
in late isolates compared to early isolates, although this difference
was not statistically signiﬁcant (Capel et al., 2012). Since we did
E. Capel et al. / Virology 444 (2013) 274–281 275not included the gag coding region in our analysis together with
the small size of our study cohort could account for this lack of
signiﬁcance. An attenuation of the HIV RC was observed for
immune-mediated escape mutations in gag restricted by protec-
tive HLA alleles (Brockman et al., 2010). Moreover, gag protein is
likely to be the most important target of HLA-restricted CTLs
(Zuniga et al., 2006). However, uncommon pathways of immune
escape may also attenuate HIV-1 integrase-mediated RC
(Brockman et al., 2012). In the present study, we investigated the
impact of the accumulation of amino acid substitutions over time
within HIV-1 integrase. We investigated integrase diversiﬁcation
in early (1993–1994) and late (2006–2007) naive samples. We
decided to study HIV-1 integrase because the ﬁrst integrase
inhibitor was approved in 2007; therefore, we could rule out an
increase in the frequency of drug resistance-associated poly-
morphisms, which could compromise integrase-mediated HIV-1
RC. Our results show that integrase-mediated RC may be decreas-
ing over time.Results
Signiﬁcant change in integrase-associated viral replication capacity
between early and late isolates
To investigate whether diversiﬁcation of the HIV-1 integrase
sequence affected ex vivo HIV-1 RC, 94 integrases were randomly
selected from two sets of samples isolated 15 years apart. Early
integrases (n¼47) were obtained from samples isolated in 1993
and 1994 from antiretroviral-naive chronically infected patients
with an unknown date of infection. Late proteases (n¼47) were
obtained from samples isolated during 2006 and 2007 from
recently infected (within the previous year) antiretroviral-naive
patients. The ﬁrst integrase inhibitor was approved in 2007;
therefore, in this study population, we could rule out an increase
in the frequency of novel secondary drug resistance-associated
polymorphisms that may compromise RC. Clinical markers of HIV-
1 infection, CD4+ T cell count, and plasma viral loads at the time of
sampling are shown in Table 1. After the construction of chimeric
viral stocks and conﬁrmation of their patient origin (Fig. 1),
recombinant viruses were used to infect a GFP-reporter T cell line
that expresses GFP when infected by HIV-1; the ex vivo RC was
then quantiﬁed over a 7-d period (Fig. 2). Chimeric viruses derived
from samples isolated in 2006–2007 displayed a signiﬁcantly
lower ex vivo viral RC compared to the viral RC of viruses from
samples isolated in 1993–1994 (p¼0.0286) (Fig. 2B). The mean7-
standard error (SE) RC of the early viruses was 0.9770.02, and
that of the late viruses was 0.9070.03. No signiﬁcant positive
correlation between RC and plasma viral load was observed
(r¼0.0877, p¼0.3996; Fig. 3A). Similarly, no signiﬁcant correlation
between CD4+ T cell count and RC was observed (r¼0.0707,
p¼0.1588; Fig. 3B).
Relationship between HIV-1 integrase sequence conservation
and viral RC
Compared to the ancestral sequence of the subtype B integrase
(http://www.hiv.lanl.gov), the mean diversiﬁcation values for the
circulating nucleotide sequences increased signiﬁcantly, from
0.02570.001 during 1993–1994 (p-distance7SE) to 0.03470.004
during 2006–2007 (po0.0001, unpaired t test) (Table 1). Diversiﬁ-
cation of the amino acid sequence also signiﬁcantly increased from
0.02870.008 during 1993–1994 to 0.03470.002 during 2006–
2007 (p¼0.0003). Genetic distances not only increased signiﬁcantly
compared to an ancestral sequence but also increased as deter-
mined by intra-group p-distance diversity. For nucleotide distances,there was an increase from 0.03270.002 to 0.05070.003 for early
and late viruses, respectively, (po0.0001), and for amino acid
distances, there was an increase from 0.03870.006 to
0.04970.007 for early and late viruses, respectively, (po0.0001).
Integrase diversiﬁcation was also highly correlated with diversiﬁca-
tion of gag or other regions of pol. However, integrase was less
diverse than that of gag or other regions of pol (data not shown) A
higher synonymous-to-nonsynonymous (dS/dN) ratio was found in
late sequences (5.870.1 and 7.370.2, for early and late viruses,
respectively; po0.0001). There was not a positive relationship
between conservation of the integrase amino acid sequence relative
to the ancestral subtype B sequence and their relative ex vivo RC
(r¼0.2967, p¼0.0037) (Fig. 4A). Similarly, a correlation was not
found for the nucleotide sequences (r¼0.1581, p¼0.1280) (Fig. 4B).
These results indicate that integrase amino acid diversiﬁcation over
time may affect the ex vivo viral RC.
Identiﬁcation of integrase amino acids associated with viral
replication capacity
We next performed an exploratory codon-by-codon analysis of
integrase sequences in the early and late datasets in order to
identify polymorphisms that were signiﬁcantly associated with
viral RC. Brieﬂy, after constructing a ML tree, ML values were
computed. When the number of nonsynonymous substitutions per
site (dN) was 43, we compared the viral RC of the recombinant
viruses carrying the amino acid substitution with the viral RC of
the recombinant viruses without this amino acid substitution
(Table 2). We found that integrase polymorphisms S17N, I72V,
S119P, and D256E were each associated with lower RC (po0.05,
unpaired t test) (Table 2). S17N, S119P, and D256E have been
described as HLA-associated polymorphisms (Brockman et al.,
2012). To assess the potential additive effects of these four
polymorphisms on integrase function, we stratiﬁed viral RC
according to the number of mutations encoded in each patient
sequence (0 to 3). We observed a statistically signiﬁcant inverse
correlation (r¼0.9699) (Fig. 5), which indicates that these four
polymorphisms may contribute additively to integrase function.Discussion
Recent work has documented that gag-protease-associated
HIV-1 or protease-associated HIV-1 RC has decreased over time.
We previously found a reduction in the protease-associated HIV-1
RC between early and late isolates; however, the difference was
not statistically signiﬁcant (Capel et al., 2012). Another study, in
which a larger number of samples were analyzed, found that the
gag-protease-associated HIV-1 RC had decreased over the course
of the epidemic in Japan (Nomura et al., 2013). However, these
studies could not rule out the possibility that an increase over time
in the frequency of secondary drug resistance-associated poly-
morphisms occurred due to the introduction of increasingly more
potent protease inhibitors. In this study, we looked for changes in
the integrase-associated HIV-1 RC between early and late isolates.
Because the samples that we analyzed were isolated before the
ﬁrst integrase inhibitor was approved, we could disregard the
possibility in this study population that there was an increase in
the frequency of novel secondary drug resistance-associated poly-
morphisms that may compromise RC.
We found that the mean integrase-mediated HIV-1 RC from
late isolates was lower than that from early samples, showing that
integrase-mediated RC may be decreasing over time. These ﬁnd-
ings extend those of Nomura et al. (2013) and conﬁrm a possible
replicative cost for HIV-1 in its adaptation to humans. We also
identiﬁed integrase amino acids that were associated with a lower
Table 1
Patient clinical parameters and integrase sequence genetic distances.
Sampling time
1993–1994 2006–2007 p values
Samples, n 47 47
CD4+ T cell counts/μl mean7SE 302.4729.24 358.4728.96 0.9380
Viral load (copies/ml) (log10) mean7SE 4.62770.1003 4.84570.1285 0.0965
Nucleotide mean p-distances7SE to ancestor 0.02570.001 0.03470.004 o 0.0001
Amino acid mean p-distances7SE to ancestor 0.02870.008 0.03470.002 0.0003
Nucleotide mean p-distances7SEa 0.03270.002 0.05070.003 o 0.0001
Amino acid mean p-distances7SEa 0.03870.006 0.04970.007 o 0.0001
Mean ds/dn7SEa 5.870.1 7.370.2 o 0.0001
ds/dn, ratio of synonymous/nonsynonymous substitutions per site; SE, standard error.
a Intrasample values.
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Fig. 1. Validation of chimeric integrase NL-43 sequences by phylogenetic analysis. Tree was drawn by the neighbour-joining method using integrase nucleotide sequences.
Unﬁlled taxon symbols indicate sequences from chimeric viral stocks. Filled taxon symbols indicate the original plasma viral sequence. The ancestral B sequence is shown in
green. Numbers 1–89 indicate viruses isolated during 1993–1994 (blue circles); numbers 90–139 indicate viruses isolated during 2006–2007 (red circles). Note that all viral
stocks and plasma viral sequences from the same subjects shared the same branches.
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E. Capel et al. / Virology 444 (2013) 274–281 277ex vivo viral RC. The results of our study thus indicate that
integrase sequence diversiﬁcation has affected ex vivo HIV-1 RC.
The results of in vivo studies that analyzed trends in the HIV-1
plasma viral load and CD4+ T cell count (two prognostic markers
of HIV disease progression) over time suggest that HIV-1 has
become more virulent during the course of the global HIV-1
epidemic (Crum-Cianﬂone et al., 2009, 2010; Dorrucci et al.,
2005, 2007; Gras et al., 2009; Herbeck et al., 2008, 2012; Muller
et al., 2006; Potard et al., 2009; Sinicco et al., 1997; Troude et al.,
2009; van Manen et al., 2011; Vanhems et al., 1999). Mathematical
modelling has also demonstrated that an increase in the parasite
dispersal rate leads to selection for increased growth and higher
virulence (Wild et al., 2009). As suggested by Nomura et al.,
ex vivo RC does not necessarily equate to viral virulence
(Nomura et al., 2013). Viral mutants may be highly adapted to
their in vivo environment. For instance, CTL or drug-resistant
mutants may be more virulent in the HLA-matched host environ-
ment or in the presence of the drug, respectively, leading to
increased virion production and thereby enhanced pathogenesis.
However, proof that lower RC ex vivo can be translated into in vivo
attenuation has come from studies of the evolution of resistance to
antiretroviral drugs, which is characterized by signiﬁcant costs in
ex vivo RC (Martinez-Picado and Martinez, 2008). It has been
suggested that drug selection of viruses with decreased ex vivo pol
RC during antiretroviral therapy may account for the sustained
partial suppression of plasma HIV-1 RNA levels in patients with
detectable drug-resistant viremia (Barbour et al., 2002; Deeks
et al., 2001). Recently, individuals who were infected by an HIV-
1 variant with a pol ex vivo RC that was signiﬁcantly lower than50 250 450 650 850 1050
CD4+ T cell count/μl
I
Fig. 3. Correlation between replication capacity of chimeric integrase NL4-3
viruses and clinical markers of HIV-1 infection. Correlation of RC of chimeric
NL4-3 with plasma viral load (A) and CD4+ T cell count (B) at the time of blood
sampling (n¼94).
Fig. 2. Comparison of ex vivo replication capacity of the 94 chimeric NL4-3 viruses
isolated during 1993–1994 and 2006–2007 from naive patients. (A) Kinetics of viral
replication. Black and red lines indicate viruses isolated during 1993–1994 and
2006–2007, respectively. (B) Comparison of slopes of the natural logs from days 3 to
7 after transfection. The RC of each variant was compared with that of the virus
with NL4-3 recombinant integrase; relative RC values are shown (n¼94). Values
represent the mean of at least three independent experiments.that of wild-type viruses had a signiﬁcantly higher CD4+ T cell
count, independent of drug resistance and plasma HIV-1 RNA
levels. This suggests that resistant viruses have lowered virulence
and are less able to deplete CD4+ T cell counts (Barbour et al.,
2004). Similarly, many HIV-1-infected patients treated with pro-
tease inhibitors develop resistant HIV-1 variants and rebounds in
viremia, but their CD4+ T cell counts often do not fall. Again, this
suggests that in these patients, T cell counts remain elevated
because the resistant virus may be attenuated in vivo (Stoddart
et al., 2001). Moreover, seminal reports that used HIV-1 competi-
tion assays in peripheral blood mononuclear cells (PBMCs) to
measure viral RC showed that many long-term survivors harbor
HIV-1 with an impaired RC, whereas rapid progressors may be
infected with HIV-1 strains that are more aggressive ex vivo
(Quinones-Mateu et al., 2000). Similarly, HIV-1 elite controllers
select for rare gag variants that have a reduced RC in tissue culture
(Miura et al., 2009). Overall, these results suggest a correlation
between ex vivo HIV-1 RC and in vivo HIV-1 pathogenesis.
Our study has some limitations that are worth noting. Although
our conclusions were supported statistically, they had narrow
signiﬁcance. In addition, since early samples were derived from
individuals at an unknown phase of infection and late samples
from recently infected individuals, it cannot also be discarded that
disease stage may have an impact on integrase function. Addi-
tional, larger studies that include more time points are needed to
extract more robust results. Our study was also restricted to a
cohort of HIV-1-infected patients who sought care at our clinic.
Samples from different geographic areas and host populations will
broaden our conclusions. However, the ﬁnding that there was a
positive relationship between the conservation of integrase amino
E. Capel et al. / Virology 444 (2013) 274–281278acid sequences and their relative ex vivo RC strongly supports the
hypothesis that HIV-1 diversiﬁcation affects viral RC.Materials and methods
Patients
This study analyzed 94 samples from 94 treatment-naive, HIV-
1-infected patients at our HIV clinic (Badalona, Spain). All patients
were infected with HIV-1 subtype B.
Recovery and analysis of HIV-1 integrase sequences
HIV-1 RNA was extracted with the QIAamp Viral RNA Mini Kit
(QIAGEN) from 140 μl of plasma and ampliﬁed by PCR with a
nested primer set. After the viral RNA was isolated, 5 ml of
resuspended RNA was reverse transcribed and PCR ampliﬁed with
the SuperScript III One-Step RT-PCR System with Platinum Taq0.8
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Fig. 4. Relationship between replication capacity and amino acid (A) and nucleo-
tide (B) sequence conservation of chimeric integrase NL4-3 viruses (n¼94).
Table 2
Exploratory analysis of integrase polymorphisms and viral replication capacity.
Patientsa Integrase codon Amino acid No. of patients
with amino acid
1993–1994 S17 N 7
1993–1994 I72 V 24
2006–2007 S119 P 10
2006–2007 D256 E 17
All D256 E 25
RC, replication capacity; SE, standard error.
a Analysis restricted to polymorphisms with a frequency of ≥3.
b p value of o0.05 was considered signiﬁcant.DNA polymerase (Invitrogen) and 10 pmol of oligonucleotides: 5I1
(sense) (5′-GGAGGAAATGAACAAGTAGAT-3′, HXB2 residues 4174–
4194) and 3I1 (antisense) (5′-GGGATGTGTACTTCTGAAC-3′, HXB2
residues 5193–5211). A second ampliﬁcation (nested PCR) was
carried out with 5I2 (sense) (5′-TTTTTAGATGGAATAGATAAGG-3′,
HXB2 residues 4228–4249) and 3I2 (antisense) (5′-TAATCCT-
CATCCTGTCTAC-3′, HXB2 residues 5075–5093). Integrase sequen-
cing was performed with the Big Dye v3.1 kit and the 3100 DNA
sequencing system (Applied Biosystems) with the ﬂanking oligo-
nucleotides 5I1 and 3I1 and the oligonucleotides 5Irv_int (5′-
TATGCTGTTTCCTGCCCTGT-3′, HXB2 residues 4504–4523) and
3IFw_int (5′-CAGGGACAGCAGAAATCCAC-3′, HXB2 residues 4908–
4927). Sequence alignment and editing was performed with the
Sequencer software program, version 4.1 (GeneCodes). Distances
were calculated using patient consensus sequences obtained from
plasma samples (see below GenBank accession numbers). Nucleo-
tide and amino acid p-distances were calculated with the MEGA
5 software package (Tamura et al., 2011).
Integrase nucleotide sequence trees were drawn by neighbour-
joining method. The HIV-1 integrase subtype B ancestral
sequences were obtained from the Los Alamos HIV sequence
database (http://www.hiv.lanl.gov/). To determine possible selec-
tive pressures, the proportion of synonymous substitutions to
potential synonymous sites and the proportion of nonsynonymous
substitutions to potential nonsynonymous sites were calculated
with the MEGA 5 software package (Tamura et al., 2011).
Identiﬁcation of integrase polymorphisms
Polymorphic sites were estimated by performing a ML analysis
of natural selection of the integrase sequences, codon by codon.
For each codon, estimates of the numbers of inferred synonymous1.5
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Fig. 5. Additive effect of integrase polymorphisms on replication capacity of
chimeric integrase NL4-3 viruses. RC were stratiﬁed according to the total number
of polymorphisms (S17N, I72V, S119P, and D256E) (Table 2) encoded by each
patient-derived sequence. An inverse association between viral RC and the number
of polymorphisms was observed.
No. of patients
without amino
acid
Mean RC7SE
with amino acid
Mean RC7SE
without amino
acid
p valuesb
40 0.8970.03 0.9870.02 0.0317
23 0.9270.02 1.0270.02 0.0015
37 0.7970.08 0.9370.03 0.0398
30 0.8270.05 0.9570.03 0.0246
69 0.8670.04 0.9670.03 0.0033
E. Capel et al. / Virology 444 (2013) 274–281 279(s) and nonsynonymous (n) substitutions were presented, along
with the numbers of sites that were estimated to be synonymous
(S) and nonsynonymous (N). These estimates were produced by
using joint ML reconstructions of ancestral states under a Muse–
Gaut model (Muse and Gaut, 1994) of codon substitution and a
general time-reversible model (Nei and Kumar, 2000) of nucleo-
tide substitution. For estimating ML values, a tree topology was
automatically computed. The test statistic dN–dS was used for
detecting codons that have undergone positive selection, where dS
is the number of synonymous substitutions per site (s/S) and dN is
the number of nonsynonymous substitutions per site (n/N). A
positive value for the test statistic indicates an overabundance of
nonsynonymous substitutions. In this case, the probability of
rejecting the null hypothesis of neutral evolution (p value) is
calculated (Frost et al., 2005; Suzuki and Gojobori, 1999). p values
of o0.05 were considered signiﬁcant. Normalized dN–dS for the
test statistic was obtained by using the total number of substitu-
tions in the tree (measured in expected substitutions per site). ML
computations of dN and dS were conducted with the HyPhy
software package (Pond et al., 2005). Evolutionary analyses were
conducted with the MEGA 5 software package.
Generation of an integrase-deleted pNL4-3 plasmid
To generate integrase recombinant viruses, a pNL4-3Δintegrase
plasmid was constructed by inserting unique BstEII restriction
sites at the 5′ and 3′ ends of the integrase gene (NL4-3 nucleotide
positions 3716 and 4350, HXB2 nucleotide positions 4337 and
4971, respectively) by site-directed mutagenesis of the wild-type
full-length HIV-1 molecular clone pNL4-3 (Adachi et al., 1986).
First, two fragments of pNL4-3 were ampliﬁed with speciﬁc
primers containing BstEII restriction sites upstream and down-
stream of the integrase gene. The plasmid pNL4-3 has two unique
restriction sites for the enzymes AgeI and EcoRI at nucleotide
positions 2863 and 5121, respectively. The upstream region of the
integrase gene was PCR ampliﬁed with Platinum Taq DNA Poly-
merase (Invitrogen) and 10 pmol of oligonucleotides: AgeIFw
(sense) (5′-CTGGCAGAAAACAGGGAG-3′, pNL4-3 residues 2834–
2851) and BstEIIRv (antisense) (5′-TACCATTTCTTTTGCTACTAC-3′,
pNL4-3 residues 3698–3718; boldface indicates site mutation to
introduce the BstEII restriction site). The downstream region of the
integrase gene was PCR ampliﬁed with Platinum Taq DNA Poly-
merase (Invitrogen) and 10 pmol of oligonucleotides: BstEIIFw
(sense) (5′-GTAGTAGCAAAAGAAATGGTAACCGTAGTAATACAAGA-
TAATAG-3′, pNL4-3 residues 4349–4372) and EcoRIRv (antisense)
(5′-GGATAAACAGCAGTTGTTGC-3′, pNL4-3 residues 5128–5147).
Each fragment was gel puriﬁed and recombined by overlapping
PCR with the external primers AgeIFw and EcoRIRv. The resulting
PCR product, called pNL4-3AgeIEcoRI, and the pNL4-3 wild-type
plasmid were then digested with both AgeI and EcoRI (New
England Biolabs). To conﬁrm the insertion of the BstEII restriction
site, PCR pNL4-3.AgeIEcoRI was further digested with BstEII
(Roche). Finally, digested fragments from both PCR pNL4-3.AgeIE-
coRI and pNL4-3 wild-type plasmid were gel puriﬁed and ligated
with T4 DNA ligase (Fermentas, Thermo Scientiﬁc) for 1 h at 25 1C
to generate the pNL4-3Δintegrase plasmid. Further digestion of the
puriﬁed plasmid with AgeI and EcoRI conﬁrmed the successful
deletion of the integrase gene.
Generation of integrase recombinant viruses and RC assay
PCR products containing full-length integrase were puriﬁed
with the QIAquick PCR Puriﬁcation Kit (QIAGEN), and 150 ng was
cotransfected into 5106 MT-4 cells (Annex III) with 1 μg of the
integrase-deleted pNL4-3 plasmid, previously linearized with
BstEII, in 250 μl of R10 Plus medium (RPMI medium with 10%fetal calf serum) by electroporation with a Bio-Rad GenePulser II
instrument. Cells were transferred to T25 ﬂasks in 10 ml of R10
Plus medium. Cell culture supernatants were harvested when the
HIV-1 p24 antigen concentration surpassed 1 μg/ml, and they were
stored at 80 1C as viral stocks for subsequent RC experiments.
Progeny virus was titrated in CEM-GFP cells, a Tat-driven GFP-
reporter T cell line that expresses GFP when infected by HIV-1
(Gervaix et al., 1997), following the Reed and Muench method
(Pannecouque et al., 2008), in which the 50% cell culture infective
dose (CCID50) value was calculated. Viral RNA was extracted,
reverse transcribed, and sequenced as described above. Viral RC
assays were performed as described previously (Brockman et al.,
2007; Miura et al., 2008; Schneidewind et al., 2007) at a low
multiplicity of infection (MOI) of 0.01, in order to minimize
potential recombination events. Moreover, the MOI of 0.01 was
chosen based on initial experiments with this cell line and the
recombinant viruses, which showed that, at this MOI, a robust and
clear exponential curve could be plotted before reaching a plateau
level of 30–40% at 7–8 d post-infection, which represents the
saturation level in this system. An aliquot of 250 μl for each culture
was harvested 3, 4, 5, 6, and 7 d after infection and ﬁxed in 1%
formaldehyde in PBS. GFP expression was monitored by ﬂow
cytometry (FACSCalibur; BD Biosciences). The slope of the natural
log of percent GFP-expressing cells was calculated between days
3 and 7 after infection. The natural log was used for the slope
calculation, which is appropriate for an exponential growth curve.
The RC of each variant was compared with that of the HXB2
recombinant protease (100%).
Statistical analysis
Statistical comparisons between two patient groups (early and
late) were performed with the unpaired t-test. A p value of o0.05
was considered signiﬁcant. Normality tests were used to deter-
mine whether data sets distribution were Gaussian (p
value40.10). Correlation analyses were performed with Pearson's
correlation. Analyses were performed with GraphPad Prism ver-
sion 4.00 for Windows. A Pearson r40.5 was considered a
signiﬁcant positive correlation.
GenBank accession numbers
The GenBank accession numbers for the sequences reported in
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